What You Ought to Know:
– OpenEvidence, essentially the most broadly used medical search and AI utility amongst verified U.S. clinicians raises $210M in Collection B funding spherical, valuing the corporate at $3.5 billion. The spherical was co-led by Google Ventures and Kleiner Perkins, with follow-on funding from Collection A pacesetter Sequoia Capital, and extra participation from Coatue, Conviction, and Thrive. OpenEvidence has now raised over $300M since its founding.
– OpenEvidence is quickly remodeling how frontline healthcare suppliers entry, consider, and apply the world’s medical data, serving to clinicians make high-stakes scientific selections on the level of care.
Fixing Info Overload with Actual-Time Proof
Clinicians are overwhelmed by data overload, with the quantity of medical analysis doubling each 5 years. Conventional medical proof databases are gradual, fragmented, and require intensive handbook looking, pulling physicians away from affected person care.
OpenEvidence addresses this by permitting clinicians to “search as soon as, skip the scavenger hunt, and floor the science in seconds”. By way of strategic content material partnerships with establishments just like the American Medical Affiliation (JAMA) and The New England Journal of Medication, OpenEvidence offers point-of-care solutions grounded within the newest analysis, full with references and follow-up strategies. OpenEvidence’s HIPAA-compliant platform quickly synthesizes medical analysis, enabling quicker, extra evidence-based selections and improved affected person outcomes by lowering the lag between new proof and bedside utility.
Launching DeepConsult™: The First AI Agent for Physicians
Along with the funding announcement, OpenEvidence introduced the vast launch of OpenEvidence DeepConsult™, the primary AI agent purpose-built for physicians. DeepConsult offers each doctor with a private, personal group of PhD-level, medically-specialized AI brokers able to conducting superior medical analysis autonomously.
These DeepConsult brokers use superior reasoning fashions to investigate and cross-reference a whole bunch of peer-reviewed medical research in parallel, surfacing not simply direct solutions but in addition novel, cross-cutting connections which may in any other case go unnoticed. This ends in an evidence-based synthesis—an integrative, interdisciplinary understanding distilled from a whole bunch of research that may sometimes take a human researcher months to supply for a single scientific subject.
Whereas OpenEvidence’s core search product focuses on pace (5–10 second solutions), DeepConsult addresses a special use case: offering complete analysis stories for advanced questions when physicians have extra time, resembling throughout a lunch break. This marks a brand new period of medical productiveness with tireless, agentic assistants.
Regardless of DeepConsult runs requiring over 100 instances the compute and value of an ordinary search, OpenEvidence is providing it solely free to all verified U.S. clinicians, no matter their establishment or office, underscoring its mission to help physicians on the level of care.
Development and Medical Adoption
OpenEvidence is actively used throughout greater than 10,000 hospitals and medical facilities nationwide and by over 40% of physicians in the USA who log in each day. The platform continues to develop by over 65,000 new verified U.S. clinician registrations every month.
The corporate has seen exponential development: in July 2024, OpenEvidence supported roughly 358,000 logged-in, verified U.S. doctor consultations in a single month. One 12 months later, OpenEvidence now handles that many consultations every workday, supporting over 8,500,000 scientific consultations by logged-in, verified U.S. physicians per 30 days—a 2,000%+ year-over-year development charge. Greater than 100 million People this 12 months will likely be handled by a physician who used OpenEvidence.
Enlargement Plans
OpenEvidence, based by Harvard- and MIT-trained PhDs Daniel Nadler and Zachary Ziegler, will use the brand new funding to increase strategic content material partnerships that improve its library of superior medical data. Daniel Nadler, founding father of Kensho (acquired by S&P World for $700 million in 2018), was additionally named to the TIME100 Well being checklist of the 100 Most Influential Individuals in world well being in 2025. Robert M. Wachter, MD, Chair of Medication at UCSF, lauded the partnership with the American Medical Affiliation as a big step in direction of fulfilling the promise of trusted, evidence-based scientific resolution help.
